ASH CONFERENCE REVIEW
During this year's American Society of Hematology (ASH) annual meeting, national experts tackled the hottest topics in hematology. Here's your conference insider. |
Top Stories |
|
Early clinical trials with checkpoint-inhibitor therapies are promising, opening the door for checkpoint-blockade combination therapies. Read more |
|
Price, comorbidities are as important as TKI choice for patients with chronic myeloid leukemia. Details |
|
Scientists explore innovative delivery systems that might one day treat hemophilia and other blood diseases. Find out more |
|
Information sharing, coordination are key to realizing the genomic revolution in medicine. Read more |
|
DISCLAIMER:
This information has been independently developed and provided by the editors of Managed Healthcare Executive. The Managed Healthcare Executive brand and this e-newsletter are in no way affiliated with the conference event or parent organization. The sponsors do not endorse and are not responsible for the accuracy of the content or for practices or standards of non-sponsor sources. These articles may discuss regimens that have not been approved by the FDA. For full prescribing information including indications, contraindications, warnings, precautions, and adverse experiences, please see the appropriate manufacturer's product circular. |
|
